lean mass retention is the number that matters
Additional indications vary between drugs, with semaglutide approved for use in 12 years and above for weight management, while tirzepatide is approved for use in 10-year-olds and above for T2DM Both medications share similar gastrointestinal side effects, which leads many patients to discontinue use, as well as boxed warnings regarding the risk of thyroid tumors
Yu M, Van Brunt K, Varnado OJ, Boye KS
While direct combination data with GLP-1 receptor agonists remain limited and still evolving, the mechanistic rationale is straightforward: if GLP-1 therapy is driving significant weight loss and a meaningful fraction of that loss would otherwise come from muscle, then supporting testosterone levels provides a biologically coherent way to shift the composition of that loss toward fat rather than lean tissue
However, resmetirom and semaglutide differ significantly in their mechanisms of action, metabolic effects, safety profiles, and potential clinical applications
Claims must include NDC, lot number, and diagnosis to support medical necessity
